Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allison M Bock

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Frontiers in Psychology|October 16, 2018
Patterning, Reading, and Executive FunctionsAllison M Bock, Kelly B Cartwright, Patrick E McKnight, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 5, 2024
Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System ProphylaxisIzel Okcu, Yucai Wang, Allison M Bock, et al.
Blood Cancer Journal|November 13, 2023
Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort studyAllison M Bock, Jennifer J Gile, Melissa C Larson, et al.
Blood Advances|April 26, 2024
Defining primary refractory large B-cell lymphomaAllison M Bock, Raphael Mwangi, Yucai Wang, et al.
Blood|September 5, 2021
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AMLFei Yang, Nicola Long, Tauangtham Anekpuritanang, et al.
Hematological Oncology|November 29, 2024
Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment ResistanceAllison M Bock, Kerstin Wenzl, Joseph P Novak, et al.
Blood Cancer Journal|July 12, 2025
Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphomaJanek S Walker, Kerstin Wenzl, Joseph P Novak, et al.
Blood Advances|June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamabAllison M Bock, Lei Feng, Ayushi Chauhan, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCLKerstin Wenzl, Matt Stokes, Joseph P Novak, et al.
Blood Cancer Journal|June 20, 2024
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCLKerstin Wenzl, Matthew E Stokes, Joseph P Novak, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Frontiers in Psychology|October 16, 2018
Patterning, Reading, and Executive FunctionsAllison M Bock, Kelly B Cartwright, Patrick E McKnight, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 5, 2024
Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System ProphylaxisIzel Okcu, Yucai Wang, Allison M Bock, et al.
Blood Cancer Journal|November 13, 2023
Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort studyAllison M Bock, Jennifer J Gile, Melissa C Larson, et al.
Blood Advances|April 26, 2024
Defining primary refractory large B-cell lymphomaAllison M Bock, Raphael Mwangi, Yucai Wang, et al.
Blood|September 5, 2021
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AMLFei Yang, Nicola Long, Tauangtham Anekpuritanang, et al.
Hematological Oncology|November 29, 2024
Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment ResistanceAllison M Bock, Kerstin Wenzl, Joseph P Novak, et al.
Blood Cancer Journal|July 12, 2025
Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphomaJanek S Walker, Kerstin Wenzl, Joseph P Novak, et al.
Blood Advances|June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamabAllison M Bock, Lei Feng, Ayushi Chauhan, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCLKerstin Wenzl, Matt Stokes, Joseph P Novak, et al.
Blood Cancer Journal|June 20, 2024
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCLKerstin Wenzl, Matthew E Stokes, Joseph P Novak, et al.
Pageof 3